AzTrials
AzTrials

Injury of Median Nerve Distal to ForearmNCT03391336

Median Nerve Injury in US-guided Carpal Tunnel Injections

An observational study of Injury of Median Nerve Distal to Forearm and Carpal Tunnel Syndrome, run by yi-chih HSU at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Carpal tunnel syndrome (CTS) is the most common nerve compression disorder in the upper extremity. It can be treated with surgical or nonsurgical methods. When nonsurgical treatment is indicated, local corticosteroid injection into the carpal tunnel can be used to reduce pain and tingling sensation. Read more about this study

Who is it for?
Ages 20 years and older
How many people
126 participants
Where
1 siteTaiwan
Study dates
1 Feb 2017to 1 Dec 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient with carpal tunnel syndrome in a single center (TSGH)

Who may be able to join

  • The clinical tests included (1) typical symptoms, eg, hand numbness and pain in the distribution of the median nerve, nocturnal worsening of symptoms, worsening symptoms while driving or gripping, (2) positive Tinel's and/or Phalen's sign, (3) failure of splinting and/or hand rest.
  • Patients with clinically suspected CTS underwent US examination.
  • The diagnoses of CTS in these patients were confirmed by US and/or electrodiagnostic investigations.

Who cannot join

  • prior carpal tunnel release
  • loss of follow-up US examinations
  • previous US-guided carpal tunnel injections
  • US-guided carpal tunnel injections with recurrence on ipsilateral hands

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • No. 325, Sec. 2, Cheng-kung Rd., Neihu 114

    Taipei, Taiwan, R.o.c., 886

Other trials in Taiwan

About this study

Carpal tunnel syndrome (CTS) is the most common nerve compression disorder in the upper extremity. It can be treated with surgical or nonsurgical methods. When nonsurgical treatment is indicated, local corticosteroid injection into the carpal tunnel can be used to reduce pain and tingling sensation.

Currently, the most widely used ultrasound (US)-guided CTS-injection method are transverse and longitudinal approach. Although we can accurately place needle within the carpal tunnel using this approach and this approach is easy to learn, median nerve injury (MNI) is still an inevitable complication and difficult to be treat.

Read more

MNI is the most serious complication associated with a local corticosteroid injection for CTS among them. A MNI will be presented with shooting pain at the injection time or transient exacerbation of CTS symptoms following the corticosteroid injection because of the pain which often masked by anesthetic during injection. Permanent damage of MN should be considered if the symptoms persist and exacerbate for more than 48 hours. A surgical intervention such as neurolysis, resection or graft repair or a gentle debridement of the crystal from the nerve may be performed in the patients with median nerve damage. Hence, early recognition of MNI before corticosteroid injection may avoid the permanent damage of MN.

Accordingly, the aim of this study is to determine the relationship between the MNI with the possible influencing factors and findings in the US-guided corticosteroid injection for patients with CTS with and to compare the therapeutic efficacy in the patients with and without MNI.

Read the detailed description

Patients:

This study was approved by our institutional review board (Tri-Service General Hospital); however, patient consent was not required for the retrospective review of records and images because patient anonymity was preserved. The patients with clinically suspected CTS evaluated by the referring neurologist (F. C. Y.), and the clinical tests included (1) typical symptoms, eg, hand numbness and pain in the distribution of the median nerve, nocturnal worsening of symptoms, worsening symptoms while driving or gripping, (2) positive Tinel's and/or Phalen's sign, (3) failure of splinting and/or hand rest. Patients with clinically suspected CTS underwent US examination. The diagnoses of CTS in these patients were confirmed by US and/or electrodiagnostic investigations.

Ultrasonography:

The US was provided using a scanner (Xario 100; Toshiba, Tokyo, Japan) with a 7~18 MHz linear transducer (PLU-1204BT). The US examinations were performed by an experienced technician (C.Y. H.) with 6 years of musculoskeletal experience in US. The technician received specialized training on the procedure used to scan the MN regarding the CTS and to record the images and was directly supervised by the attending radiologist (Y.C.H.). The US images after the US-guided hydrodissection were recorded by the attending radiologist (Y.C.H.). The diagnosis of CTS was based on qualitative US criteria, with a cutoff value of ≥12 mm2 regarding the cross-sectional area (CSA) of the MN (CSA-MN) at the inlet of the carpal tunnel. The diagnoses of CTS were confirmed by electrodiagnostic investigations in the patients with US findings of the CSA-MN < 12 mm2 at the inlet of the carpal tunnel. The flowchart illustrating patient selection is shown in Fig. 1. All US images and the measurements of cross sectional area (CSA) of the median nerve at the inlet of carpal tunnel were saved in the picture archiving and communication system (PACS). All the patients with clinically suspected CTS during the study period were examined using a standardized US protocol previously described to assess the MN at the wrist level (Figure. 1). Within 1 month after US-guided corticosteroid injection, we assessed the MN again with this manner.

Ultrasound needle guidance:

The US-guided injection procedure was performed in a standardized manner. The one-needle two-syringe technique with US guidance was used where (1) one needle is used for anesthesia, hydrodissection, and intra-carpal tunnel injection; (2) the first syringe is used to anesthetize, hydrodissect, and dilate the intra-carpal tunnel space; and (3) the second syringe is used to inject the corticosteroid therapy into the new hydrodissected space (Figure 2). After hydrodissection, the empty lidocaine syringe was detached from the needle while still in the carpal tunnel, and a 3-ml syringe prefilled with 10 mg triamcinolone acetonide suspension was attached to the indwelling needle, and the treatment was slowly injected into the hydrodissected neutral space that was closest to the MN. The injections were performed in a standardized fashion by a musculoskeletal radiologist (Y.C.H.) with 13 years of experience in US.

Smith et al have recommended the needle should be passed above and below the median nerve to fill the injectate around the median nerve with an ulnar approach. Although we can accurately place needle within the carpal tunnel using this ulnar approach and this approach is easy to learn, neurovascular injury may happened in the conditions of well-described anatomic variation (eg, persistent median artery, bifida of MN), and unable supination of wrists. In these patients with difficulty in performing hydrodissection, The investigators may abandon needle redirection deep to the median nerve or chose the radial approach when clearly identifying the fascial passage of the palmar cutaneous branch (PCB) of the MN (Figure 3). The only mater in the radial approach the investigators need attention is the avoidance of damage of the PCB of the MN.

Data collection The patients' medical records were reviewed by a neurologist (F.C.Y.). Routinely, the investigators recorded clinical data (including sex, age, and side of injection, height and weight [which were used to estimate BMI]), complications, and the effect of treatment. Blood in the needle after US-guided hydrodissection was recorded as vascular injury in the US-guided corticosteroid injection. The US images were analyzed by two musculoskeletal radiologists (Y.C.H.) and (G.S.H.) who were blinded to the occurrence of MNI. The investigators determined the absence of hyperechoic rim of MN on pre-injection US, the inter-scan change of nerve echogenicity of MN at the inlet of carpal tunnel in consensus. The investigators determined the swelling of MN including the flattening ratio (largest diameter/smallest diameter) and cross-sectional area at the inlet of carpal tunnel at the time of before and after the hydrodissection on the procedure US. The rater (Y.C.H.) performed duplicate measurements, with the second measurement obtained 2 weeks after the first. All measurements were performed with the aid of a PACS, a mouse pointer (cursor), and automated computer calculation. The mean of two measurements was considered to be the final value.

The investigators hypothesized that multiple pre-injection factors, including sex, age, side of injection, patient BMI, diabetes mellitus, anatomic variation of MN (eg, persistent median artery, bifida of MN), site of needle passed into the skin; and findings after hydrodissection such as vascular injury and the US findings of MN after hydrodissection may have relevance to MNI (Figure 4). To evaluate the relevance of these pre-injection factors to MNI, we decided to convert these continuous variables into dichotomous variables. Subjects were divided into old and young groups on the basis of a cutoff age of 40 years, thin and obese groups on the basis of a cutoff BMI of 30, ulnar and radial approaches groups on the basis of site of needle passed into the skin, hydrodissection in the superficial and deep to the median nerve groups on the basis of needle redirection.

Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) is the most commonly used questionnaire for the measurement of the severity of symptoms and functional status with reproducibility, internal consistency, and validity in patients with CTS. The symptom severity subscale of BCTQ (BCTQs) consists of 11 questions with scores from 1 point (mildest) to 5 points (most severe), and the functional status of BCTQ (BCTQf) subscale is made up of 8 questions with scores from 1 point (no difficulty in activity) to 5 points (unable to perform the activity at all). Patients were seen in the subsequent clinical visit to determine outcomes. The investigators also recorded the decrease of BCTQ between the before and after US-guided corticosteroid injection as decrement of BCTQ.

Statistical analysis All the measurements regarding the change of MN were presented as mean ± standard deviation. Intra-rater agreement was evaluated using the intra-class correlation coefficient (ICC). Fisher's exact test was used to determine the association between MNI to these independent factors before injection and findings after hydrodissection. Receiver operating characteristic (ROC) analysis was used to determine the "cut-off point" for predicting the presence of MNI. The patients with and without the diagnosis of MNI were defined as 2 groups. The therapeutic efficacy of these 2 groups were compared by using a Student t test (for BCTQ before corticosteroid injection, BCTQ after corticosteroid injection, and decrement of BCTQ), as appropriate.

All the statistical tests were performed with the SPSS software (v. 16; SPSS, Inc. Chicago, IL, USA). Significance testing was conducted using a two-tailed alternative hypothesis. Differences were considered statistically significant for a p value of < 0.05.

Keywords
Carpal tunnel syndrome, Median nerve injury, Steroids, Ultrasound, Injections
Medical subject headings
Carpal Tunnel Syndrome

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The observation of median nerve injury

    The investigators observed if patient had symptoms of shooting pain after the corticosteroid injection along with numbness, paresthesia and other sensory deficits and distributions in the median nerve supply area.

    Measured: July 2017 to September 2017

Secondary outcomes (4)
  1. The intra-rater agreement of measurements

    The investigators determined the intra-rater agreement for these quantitative measurements (flattening ratio and cross-sectional area of the MN) for the before and after hydrodissection US.

    Measured: July 2017 to September 2017

  2. The relationship between pre-injection factors and MNI

    The investigators determined the associations between MNI and the pre-injection factors. The factors includes sex, age, side of injection, site of needle passed into the skin, BMI, anatomic variation of MN, absence of hyperechoic rim of MN, and whether or not they have diabetes mellitus.

    Measured: July 2017 to September 2017

  3. The relationship between post-injection factors and MNI

    The investigators determined the associations between MNI and the post-injection factors. The hydrodissection findings includes vascular injury during hydrodissection, altered echogenicity, decrease flattening ratio, and increase cross-sectional area (CSA) of MN on US after hydrodissection.

    Measured: July 2017 to September 2017

  4. The symptoms relief after corticosteroid injection in the groups of MNI or not

    The investigators observed the symptoms relief, which was rated using a Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) scores.

    Measured: July 2017 to September 2017

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2018
  2. Study start1 Feb 2017
  3. Primary completion30 Sep 2017
  4. Study completion1 Dec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
126 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03391336
Sponsor's protocol ID
TSGHIRB 2-105-05-110
Status last verified
Dec 2017
First submitted
23 Dec 2017
Last updated
5 Jan 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Injury of Median Nerve Distal to Forearm and Carpal Tunnel Syndrome, run by yi-chih HSU at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The observation of median nerve injury (time frame: July 2017 to September 2017). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in